Welcome to the first episode of the Bite the Orange Podcast!
In this episode, we are honored to feature someone that has impacted many careers, but especially our host, Dr. Emmanuel Fombu’s trajectory in healthcare. David describes himself as a mad inventor, with 80 US patents, more of them foreign, and a whole library of published abstracts and peer-reviewed articles. He is also an incredible entrepreneur and innovator, who has sold several companies and now is leading AliveCor, and he goes deep into his entrepreneurial journey in this conversation. They talk about KardiaMobile 6L, its innovative solutions, and how it’s improving patients’ health. Together, they also discuss access and the future of medicine, specifically in the cardiovascular field.
Tune in to this wonderful episode full of advice from one of the biggest in the industry!
FULL EPISODE
BTO_David Albert: Audio automatically transcribed by Sonix
BTO_David Albert: this mp3 audio file was automatically transcribed by Sonix with the best speech-to-text algorithms. This transcript may contain errors.
Emmanuel Fombu:
Welcome to Bite The Orange. Through our conversations, we create a roadmap for the future of health with the most impactful leaders in the space. This is your host, Dr. Manny Fombu. Let's make the future of health care a reality together.
Emmanuel Fombu:
Welcome to another episode of Bite The Orange. Today we have a very special guest and someone I hold in very high regard, someone that has inspired me without knowing in my own career, personally, and someone that has led me down the path of personal clinical research, and a lot of the work that I've done and the books that I've published has been observing some of his work. He has accomplished a lot of things and should be in the golf course somewhere right now, relaxing, but he has taken the time to join us today, and this person is no other than Dr. David Albert. Dr. David Albert, you're the founder and chairman of AliveCor. And so with that being said, I'll let you introduce yourself to our audience and listeners today. So, well, first of all, thank you for joining us!
David Albert:
Well, thank you for inviting me. You know, I'm, I'm just a country boy. I've spent the last 40 years, I'm Duke Medical School class of 1981. So, you know, I'm a little older than a spring chicken, but I've spent a lot of the last 40 years developing cardiovascular medical technology. I've been very fortunate to turn a number of those developments into startups. And most recently in the past, I sold a couple of companies, including a company called Data Critical, I started, to GE Health Care and, you know, I've got 80 US patents and a bunch of foreign ones and I've published, authored or co-authored well over 100 abstracts and peer-reviewed papers. But I really, you know, I consider myself as, my, my kids say my dad's no longer a doctor, he's a mad scientist. Actually, I'm not a mad scientist. I'm mad, but I'm not, I'm an inventor. And yes, I do a lot of clinical research, but, you know, that's just what you have to do when you develop something new in medicine. You have to validate it, you have to prove that it's as good as, if not better than what exists, and that hopefully it improves efficiency, lowers costs, improves access, because, you know, health care has two sets of problems. In the developed world like the United States, it just costs too much. You know, you go into the hospital for something relatively simple and you come out with a 50,000 dollar bill. And then a lot of the developing world, there's just no access, there are no hospitals. It is, you are far from any medical facility. And so, you know, I think a number of people now, I mean, you know, 12 years ago when I started AliveCore, the notion of digital health was brand new, people thought it was, you know, was probably not real. I was told that my smartphone ECG was a toy, but today nobody thinks that. And my collaborators, whether at Mayo Clinic or GE Health Care or around the world, take it very seriously because it has the opportunity to both lower costs and improve access, solve or address the problems of the developed and the developing world. And to me, that's very exciting at this, at this stage of my game, I'm looking to try to make things a little bit better.
Emmanuel Fombu:
Thank you, Dr. Albert. And that's something that I admire. My background, my father was from Cameroon in Central Africa, and what got me very interested in digital health was because I knew when I worked in pharma, for example, in drug development, I realized that a lot of the drugs that we brought to the market, were brand new drugs, would never get to the hands of people from where I'm from. And my grandmother actually passed away in Washington, D.C. from heart failure about 15 years ago. And I realized that there was something more we could do. The younger people today, even for my age, I'm 42 years old now, but there are people younger than me that die from cardiovascular disease easily on a soccer field and any other place people die, athletes or, you know, young people doing many different things and that death is something that's real and end up in the population. So something like this, something that goes a very long way. You mentioned first as a clinician piece, I can, I could barely put IKEA furniture together. So with that being said, what got you, what in your background got you to be this inventor kind of person? But not only that, but able to actually spin these ideas into businesses that were successful, is something that a lot of clinicians think about doing but never goes anywhere.
David Albert:
Well, it was, it, it was all accidental, it was absolutely accidental. I was eight months away from finishing medical school, I was destined to become an academic cardiologist when my father, who lived half the country away, had a heart attack and when he survived, lived to be 91, he was 70 at the time, but when he was discharged from the hospital, they told him, well, you need to walk, cardiac rehab, and he lived way out in the country, walk into your heart rate gets to 120. Okay? So heart rate directed cardiac rehab, standard. But back in 1980, there were no apple watches, there were no heart rate monitors. And so I asked one of my friends at Duke, one of my classmates in medical school. He said he had a friend in graduate school, biomedical engineering who might be able to build me something. So I gave this guy a couple of hundred dollars, which, by the way, it was all my food money for a couple of months in 1980 and two months later, the guy brings me this board with a bunch of wires and says, it doesn't work, but I'm not going to work anymore on it, and I was so upset. So what I did is I took a two-and-a-half-year hiatus from medical school and went to engineering school and took undergraduate classes and graduate classes and became an engineer in addition to medical school, then I finished medical school. And by the way, I had already built an ultrasound machine that I licensed, I built a heart rate monitor that I licensed, and I went back to finish my training back home for me, which was the University of Oklahoma. And I came up with another invention. Oh, by the way, I was married, I had a little baby, and nobody wanted to license this invention from me. And I was like, wait a second, this is a great idea, this is better than my other ideas that people bought. And so I went to my wife and my parents and I said, you know, I'm going to drop out of my training program and start a company. By the way, I knew nothing about business. I knew nothing about starting a company, nothing, zero. And my mentors, both at the University of Oklahoma, late Dr. Ralph Lazzara, chief of cardiology and the late Dr. Galen Wagner at Duke, said, convinced my parents and my wife that, you know, Dave's got a plan B, he can always go back and be a doctor. So, you know, let him go do this. If he fails, it's okay. Well, that was 1987, and I've never looked back. I was very fortunate I didn't fail. And so, you know, it was not a planned trajectory for my career, it was an accidental one but it's worked. And I'm very fortunate to have the love and support of my wife and my four kids and my two grandkids. But more importantly of, of a bunch of people, there's no individual inventors in 2022, it's a team effort. And I've always had great team members who help with all the things that I can't do with skills complementary and beyond those of myself and who help me do things like a smartphone ECG or a cardio device and turn it into something that's sold, we've sold millions of them, literally millions, and have helped millions of people. And to me, you know, all over the world, we sell in over 42 countries. And we sell something for 79 dollars, so almost affordable anywhere. But certainly in terms of an EKG, the most affordable you can get. And so I'm very proud of that, that we have customers in Africa and South America and India and everywhere, all over the world, not just in New York or L.A. So I've been very fortunate, I've been able to live my dream.
Emmanuel Fombu:
And that dream also inspires other people to take that dream and move forward, right? Which is what gets people like myself, like, I mean, you know, on the steps and seeing other conditions like yourself getting more inspired, right? To get things done. I was reading a paper about you, from a background perspective where in 2019 you had about six or five patterns from then to now, you mentioned that in your 80 or 90 patents now you never stop, clearly, like.
David Albert:
No, it's, it's become, I would guess, an obsession coming up with new ideas. And I think, I've given a number of talks about what is it, what does it take to be an innovator? What does it take to be an inventor? And over 40 years, the School of Hard Knocks has taught me some, some basic lessons. And one of those I really adhere to is the notion of orthogonal thinking. And that means that if the conventional wisdom is law, is looking in this direction towards the camera, my orthogonal thinking means I'm going to approach a problem from 90 degrees away from that. I'm going to look at it differently and I'm never going to reject an idea because it's crazy because sometimes crazy ideas turn into great inventions. And so, you know, that's, that's just one of the, the tools I've used to continue to innovate as, as I approach in my advanced age.
Emmanuel Fombu:
I don't think I have an advanced age issue. I remember I think about two years ago you posted a picture. I think you went, you're exercising. And I remember there was a whole talk of everyone I saw about what? How old is he? Like what?
David Albert:
I did 65 pushups on my 65th birthday. And I work out all the time. I'm a, I was a high school and college athlete, that was a wrestler, which is known for both strength and endurance. And I've continued that because I talk all the time about healthy living and about prevention and how, you know, we have epidemics of obesity and hypertension and diabetes, and we've got to do better both in health care and just in society in general, around the world at living healthier lives. And so if I'm going to talk about that, you know, I have no credibility if I don't live it.
Emmanuel Fombu:
That's actually a great thing. When I started the podcast, I was being lazy and working out, so I decided I started tracking myself on a day to day basis because there was no way I could talk about the future of health care without actually participating in the whole effort, right? And it became a lifestyle kind of piece. And I hope that I'm able to do 65 push ups on my 65th birthday.
David Albert:
Well, it's a goal. It was a goal for me. And I was you know, I'm I think the next one is 70 on my 70th. That that may be a challenge.
Emmanuel Fombu:
Hey, I could join you on that one.
David Albert:
All right. You're on.
Emmanuel Fombu:
Yeah, it's on. I would check in on your 70th birthday and we try that together. So with that being said, with all the inventions you have, you've had, and all of the patents you've had, what has been your proudest one?
David Albert:
Well, you know, it is. There are a lot that I'm very proud of, to be honest with you, a lot that have, you know, I don't go around saying my inventions save anybody's lives. I'm very proud that a bunch of people come to me and tell me those kinds of things and that, that makes me feel worthwhile. You know, here in AliveCor, we've, we've been able to build a device and now a number of devices, a family of devices that enables people to bridge that gap between a patient and their physician in straight line. So without going through any kinds of barriers, I can get critical heart rhythm information straight from a patient to a doctor. And and I know that in certain circumstances that's been really important to the well-being of that patient. And so, you know, there are a number of patents related to that technology and those products. And I'm very, very proud of those because, again, we've been able to deliver to millions of people and, and help those people literally every day become better patients, and better patients means better outcomes.
Emmanuel Fombu:
I really love that. But I'll pick on one particular piece, the KardiaMobile 6L, which was the first FDA approved ..., personal ECG. Could you tell us about this technology and how it works, please?
David Albert:
Yeah. I mean, that was, you know, we started with a single EDECG. A lead one left arm minus right arm. And, you know, sometime about eight years ago, in about 2014, I talked to a couple of my engineers and I said, you know, I think there's there's something else we can do. Back in 1924, Ville Eindhoven of, of Eindhoven Triangle won the Nobel Prize in medicine for the first practical EKG machine. There's this big, huge contraption. You can see pictures on the Internet and three buckets of salt water, the left leg, the left hand and the right hand. He had three buckets of saltwater to record, essentially, what is the six, half the 12 EDCG, the sixth limb leads. And so I said, wait a second, you know what? If we put an electrode on the bottom of our device because it had two electrodes on top. And I said, you put that on your left knee or your left ankle. I said, we align Eindhoven's triangle. We can record half the 12 EDCG. And that just that observation, because I'm a, I'm a student of, of the history of cardiology, I have a number of cardiology history books and old textbooks, that was the genesis of what is today, the KardiaMobile 6L. And today, we can diagnose almost any kind of arrhythmia and we can monitor things that are very important, so called QT interval, which is critical because a lot of medicines that can do a lot of good can also, unfortunately cause something called QT prolongation and, and to ..., which is a, can cause sudden cardiac death. So we use those medicines when we use them and they can be all kinds of antibiotics, heart medicines, cancer medicines, psychiatric medicines. When we use those, we need to make sure we use them safely. And so the KardiaMobile 6L is now the only FDA cleared personal ECG device that can be used for monitoring in QT, and I'm very proud about that. It's being used by a variety of patient groups to keep them safe. And as we treat them, the Hippocratic Oath starts off first, do no harm. And so I'm proud because that helps us do no harm.
Emmanuel Fombu:
And Dr. Albert, that is quite fascinating, and the way you said it makes it sound easy, but it's not easy, right? Coming from that background and studying physics and even, you know, studying cardiology, an aspect of it. And it's fascinating, you know, which, which kind of brings to mind the idea of studying different domains, right? And, and the more you study on different things and outside of your own circle of confidence, you actually learn a lot more from those particular areas. And we mentioned like QT interval or QT prolongation, that's something that's a lot of oncology drugs actually lead to QT prolongation in places, right, where a lot of cancer should be monitored in this particular case outside of cardiology.
David Albert:
Well, that's exactly right. In fact, there's a cancer drug called Kisqali by Novartis. It's used for, for breast cancer. And, and Kisqali patients get KardiaMobile 6Ls because it can prolong the QT. You don't want to say, well, we beat your cancer, but you died of sudden death, no, that's not a good outcome. So we're, we're working with Novartis and those, those oncologists to keep their patients safe as they treat those cancers. And so there are other drugs. There are a number of them. You know, you mentioned your mom passed away from heart failure, as did my dad at 91, but.
Emmanuel Fombu:
My grandmother.
David Albert:
Your grandmother, your grandmother, sorry, your grandmother, it was my father, I'm an old guy. So but, but, you know, one of the things, one of the things that's problematic is a lot of cancer drugs can cause heart failure. Adrian Meissen, there are a number of them, a whole families of, of cancer drugs that are very effective cancer drugs, but that also have an impact on the heart function. And so there's a lot of opportunity for us to monitor them because you want to use those drugs, you want to use them as aggressively as you can. But again, you want to keep the patient safe. You don't want to cause them to have heart failure. So a lot of opportunities to monitor therapies and keep our patients safe. And I think AliveCor, you know, both today and into the future, will be expanding that type of, of application.
Emmanuel Fombu:
And just to expand on that, it's interesting, I used to work on Novartis actually, on the cardiovascular side of it, I remember because Kisqali getting in the market and I've been, I was pulled over from the cardiovascular unit to the oncologist side, I actually work with oncology team to identify such technologies that I'm glad that this is actually going on and some real time to use by patients. But with that being said, going through the whole due diligence process to identify a good solution like a KardiaMobile, for example, right, 6L, how, can you explain to the audience that is listening right now there might not be cardiologists as ourselves, the difference between a single lead and a six lead ECG?
David Albert:
Certainly. Well, a single lead ECT, whether it's a KardiaMobile or an Apple Watch or any one of the smartwatches that incorporate EKG is, is basically one view of the heart. And the hearts of three dimensional structure, right? And one view of the heart is valuable. I've had people in the beginning, 12 years ago say a cardiologist gets up at a meeting and says this is just one lead, this is not a 12 lead ECG, which gives you 12 views of the heart. And I go, that's right, however, how many leads does an automatic external defibrillator use to decide it's going to save your life? The answer is one.
Emmanuel Fombu:
Correct.
David Albert:
How many leads does an implantable cardiac defibrillator use to save your life? One. So there's an awful lot of very valuable information in the lead. However, it is a very incomplete view. And so the more perspectives we have on this three dimensional structure and the electrical activation of that structure, the more complete our information is and the six-lead ECG provides you six different views from six perspectives instead of a single one and, and without question gives you a more complete answer. Now, it's not quite a 12-lead ECG, I'm not going to say it is. There's still things a 12-lead ECG can do, such as diagnosing all types of heart attacks, coronary, coronary artery occlusions. However, it's, the six lead is significantly better at diagnosing a lot of conditions than a single lead. And, and obviously, if we go from a single lead to a six lead, we're still not a 12 lead. But maybe sometime in the future there'll be something like a 12 lead, that again, is I think one of the things we pioneered is having the patient be, have it, be a personal device that is intuitive to use, that is easy, that doesn't require prepping and wet electrodes and things. And so obviously, I can tell you if AliveCor introduces something, it will be revolutionary easy to use. And I think you can take that to the bank.
Emmanuel Fombu:
Gottcha, and so with that being said, ... single lead ECG to a six ECG, clearly doesn't challenge us. I mean, we currently have 12 lead ECGs, I mean, you put them on your chest. But the point is a wearable kind of device and things that you take around with you moving around. What are some of the challenges getting to that 12 lead ECG? Is it a technology advancement piece? Is it the physics of it? What is that main challenge?
David Albert:
It's, it's all, it's all of the above. But, you know, you need, 12 lead ECGs require very precise lead placements on the body, require conventionally what we call disposable wet electrodes that use something called .... chloride and gel and what, lead wires going to a device. And so obviously being able to deliver equivalent information yet do so in a very easy to use manner will require some innovation. And I'm, I'm, let's just say I'm cautiously optimistic that AliveCor will be able to provide all kinds of EKGs and be able to continue to push the quality of the information we deliver both to the patients and to their doctors. So, you know, there's, there's physics involved, there's biology involved, there's human psychology involved in having somebody use something on themselves, especially when they're in some kind of acute conditioning. They would be having a heart attack, they may be having an arrhythmia and having it be easy enough that someone, even in acute distress, can use it accurately, you know, you've got to get inside the human mind to, to create that kind of innovation. And I think in 12 years we've proven at least we have some talent there.
Emmanuel Fombu:
Which is quite interesting. When I, when I listen to someone like you speak, or Eugene Braunwald, for example, in cardiology, I always, then it makes me become a strong believer in Elon Musk's Neuralink, the idea of downloading the brain and having a historical piece of things that you've learned. In the past that, no one today could possibly know, I mean, even experience is dealing with humans, some people, in developing.
David Albert:
By the way, you bring up Dr. Braunwald. You know, I told you about that cardiologist at a meeting back in 2012 saying it's not a 12 lead ECG, it's just one lead, and I told you my response. Well, that was in a meeting, Heart Failure Society of America, Heart failure, you know that meeting. And the chair of my session sitting next to me was Eugene Braunwald. And of course, what did I do? I brought my two volume heart disease to the meeting and I had him autograph it to me. So as I was giving my talk and then answering the post, post talk questions from the guy in the audience about it, it's now 12 lead. Dr. Braunwald, well, you know, afterwards said, good answer. So I take that, that's the ultimate compliment. Eugene Braunwld telling you, you had a good answer.
Emmanuel Fombu:
It is. It's an honor. And it's always great to hear the stories and it's fascinating stories. And I think any other younger medical student or any other clinician of the resident listen to the story, I think it's quite inspiring to see that kind of interaction actually take place. So with that being said, with all the experience you have, where do you see this world of remote monitoring and cardiovascular monitoring going in the next 12 years?
David Albert:
Well, we're just at the beginning. You know, we're, we're going to we're going to struggle through issues like who's going to pay, reimbursement. You know, in this country, we have codes around the rest of the world, much of the world you have government funded health care and, and budgets. And so we're going to work our way through this, you're going to have people who, who, if we make something inexpensive enough, then everybody can have access to it. And I think one of the things that I realized early on that people now I think almost take for granted is, you know, in much of the world, we're not going to build huge hospitals, ivory towers and, and your portal to health care will be your smartphone and it will do monitor you, it will deliver you prescriptions, it will be your interface, like the interface we're having right now, two way audio-video interface with your health care providers, with your physicians. And I think the pandemic, you know, it's been a terrible struggle for two years around the world. But one thing it did is it showed the promise of virtual care. And I think we're not going to go back. You know, in-person care is certainly coming back to, to, to higher levels than it was for two years. But we now know the value of virtual care in many situations. And given the power of smartphones, the power of sensors, the power of digital therapeutics, you know, it's, it's, it's only going to continue to evolve to where your first, you know, people joke, doctors joke about doctor Google, the patient brings in and tells me doctor Google says I have cancer when what they've got is a toothache, that will evolve. And you know, you've got tech companies like Amazon buying One Medical, you know, you've got all kinds of, Apple in health care and, and Facebook collecting tremendous amounts of information. The tech companies will be involved in health care, and that will push the traditional medical companies. The JNJs, Medtronics, Novartis's into the digital domain, as it already has, and that's only going to accelerate. So I think digital health will simply evolve into health.
Emmanuel Fombu:
That is quite interesting. It looks like we're at this crossroads right now, right? Where you have for the medical device companies and the consumer health kind of market and how you kind of fit in, right? And I think there's a big challenge right now about evidence generation where people think, well, if I mean, well, at the same time, the many people in this space are very excited when Google say something, right? And they think, for example, when Amazon, Apple came up with the Apple Watch piece everyone thought AliveCor was dead, right? Without knowing the intricate details of what was special about the six leads to ECG, and how are you able to do it.
David Albert:
I mean, we, we've grown hundreds of percent since Apple introduced three ECG. And, you know, we have over 200 peer reviewed publications, validation is still critical. Credibility among the medical community is critical. And I think, you know, if we're an example of anything, we're an example of don't lead with a press release, lead with clinical study. And that's how you will succeed in in medicine and in digital health.
Emmanuel Fombu:
And that is quite fascinating. And that brings us to our last question here. Clearly, you have an incredible career and clearly the experience that you've shared with all of us, I think, doesn't only apply in the field of cardiology, but across the world of innovation. So someone listening right now, you probably inspired them just like you inspired me. But with that being said, what would you say has been the most memorable and exciting moment of your career? No that your career is over, I'm sure your career is still going on.
David Albert:
Well, I think it's, one of the most memorable ones was in, in December 30th, 2010, I went into my office and made an unscripted four minute video describing this new smartphone ECG case. And as I was, and by the way, my nine year old son, who's today a senior at Harvard, taught me how to make a YouTube video and upload it because he did Nerf gun modifications, and thank you, Luke Albert. And so as I was up, getting ready to upload it, there was a box that said, send this link to your LinkedIn connections. I didn't have any social media, I had about 300 LinkedIn connections in 2010, which was business people from GE and medical device companies, and I just happened to click that. I don't even know why and I said upload it, uploaded and I went home and 24 hours later I get a call from my partner who lives in Australia and he said, mate, what did you do? And I go, I don't know. What do you mean, what did I do? I made a video because I'm going to the Consumer Electronics Show and there were going to be three or four companies that weren't going to be there that I wanted to show this new invention to. He said, we have 100,000 views, and then we had 300,000 views. And then I got called by Fox and Friends and CNN and all these people, and my video went viral. And in the course of four or five days, a half a million views, which in 2010 was a lot for this medical invention on a smartphone, and that was the beginning. It was, I learned that a viral epidemic of ideas is different than a viral epidemic of a true virus, and one is can be very deadly and the other can be very beneficial. And I was the beneficiary of an idea epidemic that went viral. And so that to me, that was incredibly exciting and, and was totally unknown to the kind of more bland area of medical devices where you plod through. Oh, by the way, when I was at the Consumer Electronics Show and all this, I was on TV and all this stuff, I got a call from the FDA saying, what are you doing, Dave? I worked with the FDA for years and I said, you don't understand, I have no idea how this happened, this was not on purpose. And they just said, you know, you're not supposed to do this. I said, I didn't do anything. I didn't, this, you guys are going to have to deal with the new reality. And today they have a whole digital health division and everything. You know, they realized, you know, how did something go viral? Well, today, if you're on TikTok, you know, things can have a million views in 10 minutes. It's, it's a different world, but back 12 years ago, it was something unique. And so that was, that was really an incredible experience for me and something I definitely over my career wasn't used to.
Emmanuel Fombu:
And that's a fascinating story and it ties in perfectly, a perfect way to round this particular episode. And I told you earlier, and I make a commitment here, I'm actually switching this episode to be the very first episode released on my show. And the reason why, I think this is this conversation today is it's a memorable moment for me as well. And I think it fits the particular concept of why the podcast is called Bite to Orange and to think different, right? And I think the concept that, that you explained is exactly what we're trying to do here, to get people to understand that they could think different, to listen to those innovators, the people that are out there to help try to drive this change by thinking different and together, it's the whole idea of starting a movement, right? And so we encourage people on the show, if you believe in transforming healthcare and thinking different, just take a bite of an orange and we are creating hopefully you could take a bite out of the orange instead of a photograph of it. I'm going to create a movement with like, the first podcast called #BiteTheOrange, and we're going to support everyone. And I believe everyone listening today should be inspired and together we could make the future healthcare reality. So thank you, Dr. Albert, and we'll look forward to getting a picture you of biting the orange.
David Albert:
Well, I will. I got to get an orange and I will bite it and get a picture to you and thank you for this opportunity. It's been a great time. I really appreciate it.
Emmanuel Fombu:
Thank you. I appreciate it. Thank you very much.
David Albert:
Take care.
Emmanuel Fombu:
Thank you. Bye bye.
Emmanuel Fombu:
Thank you for listening to Bite the Orange. If you want to change health care with us, please contact us at info@EmmanuelFombu.com, or you can visit us at EmmanuelFombu.com or BiteTheOrange.com. If you like this episode and want more information about us, you can also visit us at EmmanuelFombu.com.
Sonix is the world’s most advanced automated transcription, translation, and subtitling platform. Fast, accurate, and affordable.
Automatically convert your mp3 files to text (txt file), Microsoft Word (docx file), and SubRip Subtitle (srt file) in minutes.
Sonix has many features that you'd love including automatic transcription software, advanced search, transcribe multiple languages, world-class support, and easily transcribe your Zoom meetings. Try Sonix for free today.
About David Albert
David E. Albert, MD, an Oklahoma native, is a physician, inventor, and serial entrepreneur who has developed life-saving technologies and products over the last 30 years, turning a number of those innovations into tech startups. Today, he is the founder of three technology companies, InnovAlarm, Lifetone Technology, and AliveCor. His previous startups include Corazonix Corp (sold to Arrhythmia Research Technology) and Data Critical (sold to GE). Dr. Albert left GE in 2004 as Chief Scientist of GE Cardiology to disrupt several new markets.
His latest invention, AliveCor’s KardiaMobile personal ECG technology, became a global sensation via a YouTube Video in January 2011 around the Consumer Electronics Show and was featured on ABC, CBS, CNN, and Fox News among many other media outlets. Dr. Albert has 32 issued US patents, a large number pending, and several new “secret inventions” in development. He has authored or co-authored over 50 scientific abstracts and publications, principally in the cardiology literature. Dr. Albert has lectured at the Entrepreneurship programs at the MIT Sloan School and the University of Oklahoma. Dr. Albert graduated with Honors from Harvard College and from Duke University Medical School.
Things You’ll Learn
In medicine, every invention has to be validated and proved.
Healthcare in the US has one problem: cost.
In the developing world, the problem of healthcare is access.
In 2022, no one is a solo inventor, everything happens in groups.
Many cancer treatments are really effective for cancers, but can lead to sudden death due to heart failure.
As bad as the pandemic was, it showed the promise of virtual care.
To succeed in the digital health space, you must lead with the clinical study, not the press release.